PARP inhibitors for cancer therapy / Nicola J. Curtin, Ricky A. Sharma, editors.
"PARP Inhibitors for Cancer Therapy provides a comprehensive overview of the role of PARP in cancer therapy. The volume covers the history of the discovery of PARP (poly ADP ribose polymerase) and its role in DNA repair. In addition, a description of discovery of the PARP family, and other DNA...
Saved in:
| Other Authors: | , |
|---|---|
| Format: | Ebook |
| Language: | English |
| Published: |
Cham :
Humana Press : Springer,
[2015]
|
| Series: | Cancer drug discovery and development ;
v. 83. |
| Subjects: | |
| Online Access: | Springer eBooks |
Table of Contents:
- What PARP is and What it Does:
- History of the Discovery of Poly (ADP-ribose) / Takashi Sugimura, Sydney Shall
- Discovery of the PARP Superfamily and Focus on the Lesser Exhibited But Not Lesser Talented Members / Eléa Héberlé, Jean-Christophe Amé, Giuditta Illuzzi, Françoise Dantzer, Valérie Schreiber
- The Role of PARPs in DNA Strand Break Repair / Stuart L. Rulten, Françoise Dantzer, Keith W. Caldecott
- TIPs: Tankyrase Interacting Proteins / Susan Smith
- PARP and Carcinogenesis / Junhui Wang, Akira Sato, Hiroaki Fujimori, Yoshio Miki, Mitsuko Masutani
- Multitasking Roles for Poly(ADP-ribosyl)ation in Aging and Longevity / Aswin Mangerich, Alexander Bürkle
- NAD Catalysis and the Identification of Inhibitors:
- Overview of PARP Inhibitor Design and Optimization / Dana Ferraris
- Structure Based Design of PARP Inhibitors / Stacie S. Canan
- Chemo- and Radiosensitisation in Vitro and in Vivo:
- Preclinical Chemosensitization by PARP Inhibitors / David R. Shalinsky, Cherrie K. Donawho, Gerrit Los, Joann P. Palma
- Classification of PARP Inhibitors Based on PARP Trapping and Catalytic Inhibition, and Rationale for Combinations with Topoisomerase I Inhibitors and Alkylating Agents / Junko Murai, Yves Pommier
- Radiosensitisation by Poly(ADP-ribose) Polymerase Inhibition / Charles Fouillade, Alexis Fouquin, Mohammed-Tayyib Boudra, Vincent Favaudon, Vincent Pennaneach, Janet Hall
- The Vasoactivity of PARP Inhibitors / Cian M. McCrudden, Kaye J. Williams
- Synthetic Lethality:
- Synthetic Lethality with Homologous Recombination Repair Defects / Helen E. Bryant, Sydney Shall
- Targeting Tumour Hypoxia with PARP Inhibitors: Contextual Synthetic Lethality / Katarzyna B. Leszczynska, Nadya Temper, Robert G. Bristow, Ester M. Hammond
- Other Determinants of Sensitivity / Naoyuki Okita, Atsushi Shibata
- Synthetic Sickness with Molecularly Targeted Agents Against the EGFR Pathway / Jennifer A. Stanley, Eddy S. Yang
- Disruption of DNA Repair by Cell Cycle and Transcriptional CDK Inhibition / Liam Cornell, Neil Johnson, Geoffrey I. Shapiro
- Resistance to PARP Inhibitors Mediated by Secondary BRCA1/2 Mutations / Kiranjit K. Dhillon, Toshiyasu Taniguchi
- PARP Inhibitor Resistance—What Is Beyond BRCA1 or BRCA2 Restoration? / Guotai Xu, Jos Jonkers, Sven Rottenberg
- Clinical Status:
- Introduction to PARPi Clinical Trials and Future Directions / Ruth Plummer, Yvette Drew
- Clinical Trials Investigating PARP Inhibitors as Single Agents / Sheena Irshad, Andrew Tutt
- Clinical Trials of PARP Inhibitors with Chemotherapy / Ashley K. Clift, Nicholas Coupe, Mark R. Middleton
- Combination of PARP Inhibitors with Clinical Radiotherapy / Ross Carruthers, Anthony J Chalmers
- Biomarkers for PARP Inhibitors / Charles Dearman, Ricky A. Sharma, Nicola J. Curtin.